Advanced. Total Funding Amount $41.6M. Summary Financials People Technology Updates. Try Pro free Solutions Products Resources Pricing Log In Rocket Pharmaceuticals. Rocket Pharmaceuticals Ltd. operates in the healthcare industry focusing on biotechnology business.Rocket Pharmaceuticals is an emerging biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases.

application.

The Company’s lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The Company is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. Crunchbase Enterprise users can access unlimited exports.At this time, we accept credit card payments through Yes, annual subscriptions will auto-renew after each billing cycle.Crunchbase Pro was built on top of our Crunchbase data to give our users more functionality. Rocket Pharmaceuticals has 1 board member or advisor, Naveen Yalamanchi. http://tfpharma.com/wp-content/themes/tfpharma/img/logo.png By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. Funding Rounds . Crunchbase Enterprise is built for teams and gives you access to our full dataset via API or CSV export, integration with Salesforce, and multiple Pro seats.API access is not included with Crunchbase Pro.

Rocket Pharmaceuticals Rocket Pharmaceuticals Ltd. operates in the healthcare industry focusing on biotechnology business. At Orchard, we measure our impact in lifetimes. Inspiration and Impact. Rocket Pharmaceuticals is ranked 2,203,897 among websites globally based on its 5,995 monthly web visitors, according to SimilarWeb. Search Crunchbase. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1) and Infantile Malignant Osteopetrosis. Seed, Series A, Private Equity)Whether an Organization is for profit or non-profit Free trial users are not able to export any results. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for … And he just went public with what he predicts will be his next big winner.Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a rare monogenic red blood cell disorder.Market Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVADiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGM - NasdaqGM Real Time Price. Rocket solves recruiters’ needs by allowing them to evaluate the entire talent pool and find best matches instantly. Try Pro free Solutions. UroGen Pharma is pioneering new treatments for improved care. Save. Upgrade to Pro to access the expansive Crunchbase dataset to uncover the companies, people, and news that matters. Rocket Pharmaceuticals is an emerging biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Number of Funding Rounds 2. With Crunchbase Pro you will receive access to advanced search, charts on company profiles, statistics, alerts, premium data filters, and the functionality to export to CSV.

The Empire State Building 350 Fifth Avenue Suite 7530 New York, NY 10118. Rocket Pharmaceuticals Ltd. operates in the healthcare industry focusing on biotechnology business. Target your search with intuitive filters & unlimited results ; Announced Date Sep 12, 2017 Completed On Date Jan 4, 2018 Acquisition Type Acquisition Acquisition Status Complete Disposition of Acquired Organization Subsidiary Rocket Pharmaceuticals . Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast.